Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
November 05, 2020 16:01 ET
|
Fate Therapeutics, Inc.
First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia First...
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting
November 05, 2020 08:00 ET
|
Fate Therapeutics, Inc.
Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO, Nov. 05, 2020 ...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results
November 02, 2020 07:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
October 15, 2020 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
September 30, 2020 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces September Investor Events
September 04, 2020 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
August 19, 2020 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
August 05, 2020 16:01 ET
|
Fate Therapeutics, Inc.
Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for...
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
July 29, 2020 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...